Konwave ATG Emerging Markets Healthcare

Factsheet August 2026 · as of 31.08.2026

This document is a marketing communication

FUND DESCRIPTION

Investment Objective:

The Fund aims to achieve attractive long-term capital appreciation and seeks to outperform its benchmark over rolling three- and five-year periods. It targets an annual outperformance of 2% to 3% after fees.

Philosophy:

The Fund follows a disciplined bottom-up investment approach based on the proven GARP philosophy (Growth at a Reasonable Price), combining the opportunities of high-growth companies with attractive valuations. Investments are selectively made in listed small-, mid-, and large-cap companies in the healthcare sector across Emerging Markets. ESG criteria are firmly embedded in the investment process and support responsible and sustainable security selection.

Investment Strategy:

To achieve its investment objective, the Fund invests at least 80% of its net asset value in equities of healthcare companies from Emerging Markets. The focus is on promising companies in the pharmaceutical, biotechnology, medical technology, and healthcare services sectors, as well as related areas such as diagnostics, digital health companies, and contract manufacturers. The portfolio is constructed with a focused approach and typically comprises 30 to 50 carefully selected individual positions.

MONTHLY PERFORMANCE

USD -F-	Dec 25*	Jan 26	Feb 26	Mar 26	Apr 26	May 26	Jun 26	Jul 26	Aug 26	YTD
Konwave ATG EM HC	-3,66%	3,56%	0,08%	-8,80%	3,59%	-4,26%	-1,53%	4,49%	7,16%	3,35%
MSCI EM HC	-4,51%	3,16%	2,89%	-9,96%	3,98%	-2,89%	0,10%	5,12%	8,68%	10,35%

* Inception 4/12/2025

COUNTRY ALLOCATION



SECTOR ALLOCATION



ATG Healthcare Investments AG
Klausstrasse 26, 8008 Zürich
Switzerland

+41 43 234 57 40
info@atg-healthcare.com
www.atg-healthcare.com

Konwave ATG Emerging Markets Healthcare

Factsheet August 2026 · as of 31.08.2026

This document is a marketing communication

FUND DATA

NAV / ISIN / Sedol USD F ACC **USD 99,57 /**	IE000500SX60 / BW2FJY3
ISIN USD I ACC	IE000TFAVGX2
ISIN CHF I ACC	IE00006NU398
ISIN EUR I ACC	IE000L47KBG2
ISIN CHF Q ACC	IE000LKCWQ93

Type	**Open end**
Domicile	**Ireland**
SFDR Classification	**Article 8**
Custodian	**Northern Trust International Fund Administration**
Fund Mgmt Company	**Harrington Cooper UCITS Funds ICAV**
Investment Manager	**ATG Healthcare Investments AG**
Auditor	**Deloitte Ireland**
Management fee	**0,6%-0,8%* p.a. (F) 0,9% p.a. (I) / 1,5% p.a. (Q)**
Adm. / Custody fee	**ca. 0,2%** p.a.**
Pricing / Cut-Off	**Daily / 12:00 Noon (Ireland)**
Issue fee	**0%**
Redemption fee	**0%**

* Depending on Fund Size
** Estimate

TOP-TEN HOLDINGS

COMPANY	COUNTRY	WEIGHT
Wuxi Biologics	China	9,0%
Celltrion	South Korea	7,0%
Innovent	China	6,8%
Sichuan Kelun Biotech	China	6,5%
BeOne	China	5,2%
Sun Pharmaceuticals	India	5,0%
Wuxi Apptec	China	4,7%
Samsung Biologics	South Korea	4,6%
Hansoh Pharmaceutical	China	4,1%
PharmaEssentia	Others	3,4%
Total Top 10		**56,1%**

STATISTICAL DATA (USD –F-)

Annualised return	**n.a.**
Return since inception	**-0,43%**
Inception date	**4.12.2025**
Volatility	**n.a.**
Information ratio	**n.a.**
Tracking error	**n.a.**
Fund size (all share classes)	**USD 54,4mn**

COUNTRY ALLOCATION

China	**54,7%**
India	**18,6%**
South Korea	**14,6%**
Brazil	**1,4%**
Others	**9,7%**
Cash	**1,0%**

MARKET CAPITALISATION ALLOCATION

Large Caps (>20bn USD)	**55,3%**
Mid Caps (5 – 20bn USD)	**37,2%**
Small Caps (< 5bn USD)	**6,5%**
Cash	**1,0%**

ATG Healthcare Investments AG
Klausstrasse 26, 8008 Zürich
Switzerland

+41 43 234 57 40
info@atg-healthcare.com
www.atg-healthcare.com